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Overview
• Treatment and monitoring of Bipolar Disorder 
o Lithium therapy for mood stabilisation
o Non-invasive sampling of patient
• Chemo/Bio-markers for Bipolar patient monitoring
o Fluorescent detection of Lithium
o Colourimetric determination of α-amylase
• Portable analysis of Bipolar disorder using multi-analyte platform
• Detection of Chemo/Bio-markers using mobile platform
• Conclusions and future applications
Treatment and monitoring of Bipolar 
Disorder
Lithium treatment for mood stabilisation
• Current treatment of  Bipolar disorder involves administration of Lithium in the form of 
lithium carbonate tablets.
• Typical serum (blood) levels range between 0.6 – 1.3mmol1 with toxic levels above 
1.5mmol1
 narrow therapeutic/toxic range
Two issues from current methods of monitoring dosage:
1. Blood typically drawn ONCE weekly to determine lithium levels in patient.
 Risk of overdose/intoxication event being missed by infrequent monitoring
2. Invasive nature of blood drawing procedure.
 Discomfort associated with blood sampling
1 R. Regenthal et al, J. Clin. Monit., 1999, 15, 529-544
Bipolar Disorder
Non-invasive sampling of patient
• Invasive nature of drawing blood limits 
number of samples and decreases patient 
compliance.
• Interest in alternatives to Blood analysis 
sought for conditions requiring frequent 
analysis such as Diabetes.
• Saliva chosen due to ease of accessibility, low 
sample preparation requirements and 
minimal invasiveness.  
Blood (Top): http://www.ivteam.com/tourniquet-application-time/ <accessed 11/06/12>
Bio/Chemo-markers for Bipolar 
Patient monitoring
Chemical marker: Lithium 
• Uncommon element in body resulting in minimal 
interference due to alternate sources of lithium.
• Readily found in bodily fluids during treatment; urine, 
saliva, blood and sweat. Typically found to be in higher 
concentration in saliva than blood
Biomarker: α-amylase
• Present in blood (Pancreatic) and saliva (salivary)
• Salivary α-amylase found to exhibit sensitivity to stress.
• Proposed use as stress monitor in conjunction with other 
methods of mood analysis (psychiatric assessment, vocal 
pattern analysis) .
Lithium (top): http://www.sciencephoto.com/image/111204/530wm/C0046993-Lithium_Carbonate-SPL.jpg <accessed 14/06/12>
Amylase (bottom): http://www.salimetrics.com/my-spit-research/analytes/a-amylase.php <accessed 11/06/12> 
Fluorescent Detection of Lithium
• Highly sensitive method using ‘dark background’ and lithium specific probe dye.
• 1,4-Dihydroxyanthraquinone (Quinizarin) found to preferentially complex with Lithium
• Complex absorption at 605nm and corresponding emission at 624nm
Quinizarin dye and Lithium complex formation
Fluorescent Detection of Lithium
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Colorimetric determination of α-amylase
• Exploitation of α-amylase enzymatic break down
of starch.
• Water insoluble starch polymer with attached
blue dye is added to aqueous saliva sample.
• As the starch is broken down, the dye is released
into the water resulting in colour change.
• Measurement of absorption at 620nm allows for
the determination of amylase concentration in
saliva.
Colour change in α-amylase  concentrations in response to 
stress
1.2U/ml0.5U/mlBlank
Colorimetric determination of α-amylase
Absorption changes related to varying levels of amylase present in 
saliva throughout a day (healthy individual)
Characteristic absorption spectra of released blue due following 
breakdown of starch polymer backbone. 
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Portable analysis of Bipolar disorder 
using multi-analyte platform
Portable analysis of Bipolar disorder 
using multi-analyte platform
• Wireless microcontroller (Wixel©) with dual LED system and individual photodiode 
detectors optimized for each target marker.
• Automated Software programme:
- ‘li’ (lithium) and ‘aa’ (-amylase) commands initiate custom measurement routine.
- 180s settling time hard coded to device for lithium analysis.
- 20 individual measurements printed to screen
- Device calculates average and prints to screen.
Portable analysis of Bipolar disorder 
using multi-analyte platform
Fluorescence:
Lithium detection
Ex: 605nm
Em: 624nm
Absorbance:
α-amylase detection
Abs: 0
Blue dye released by 
starch breakdown
‘Li’aa’
Determination of Chemo/Bio-
markers using mobile platform
• Standard addition technique to determination of lithium levels:
 Increasing addition of stock solution containing lithium of known concentration added to saliva sample 
containing unknown lithium concentration.
 Validation versus standard method (ICP-AES)
Standard addition curve for the determination of unknown saliva lithium 
concentration 
sample concentration (mM)
Known saliva concentration 1.00
Portable platform 
measurement 1.06
ICP-AES measurement 0.93
standard deviation 0.09
Determination of Chemo/Bio-
markers using mobile platform
• Calibration curve for determination of α-
amylase:
 Calibration curve constructed using human amylase 
standard
 Device optimised for determination of alpha-
amylase levels within specific range (0.1 U/mL – 1.2 
U/mL)
 Clinical trials in progress. Calibration curve of amylase using portable platform
(a) UV-Vis spectra of amylase standards. (b) Calibration curve for validation using UV-Vis
Conclusions and future applications
• Use of Non-invasive sample for increased frequency of patient monitoring . 
• Reliable Portable optical detection of both chemical and biological markers for 
eventual Reduction in requirement for hospital visits with patients able to 
determine levels at home.
• Customisable nature of device allows for the potential of tailoring the system 
(LEDs and detectors) to alternative targets that can be detected optically allowing 
for use with other disorders.
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